IELSG40A phase II trial addressing feasibility and activity of clarithromycin + lenalidomide combination: a full oral treatment for patients with relapsed/refractory mucosa-associated lymphoid tissue (MALT) lymphoma (CLEO trial)
Participants required:62 (patients enrolled: 44 – enrolment discontinued per protocol, after the interim analysis)
Investigator responsible(s):A. Ferreri, M. Raderer
Objective(s):To assess the overall response rate (complete and partial responses) of the combination treatment of clarithromycin and lenalidomide in patients with MALT lymphoma, refractory or relapsing after radiotherapy and/or chemotherapy and/or immunotherapy.

Home | Go to Studies